What question did this study set out to answer?

The aim is to identify new biomarkers that enhance early diagnosis and risk stratification in acute coronary syndromes.

March 1, 2002American Journal of Critical Care

Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A

View Full Paper

Ask AI

Bookmark

Why the study?

Do novel biomarkers (PAPP-A, hs-CRP, d-dimer, BNP) improve early diagnosis and risk stratification in patients with acute coronary syndrome compared to traditional markers?

Population

Patients with acute coronary syndrome, including unstable angina and acute myocardial infarction

Comparison

Novel biomarkers of plaque inflammation and… vs Traditional serum markers of myocardial injury

Design

Review

Authors

LFLaurie G. FuttermanUniversity of Miami LLLouis LembergUniversity of Miami

Discussion

Member takes

Implication

May support pre-necrosis ACS risk stratification; leaves open prospective validation before practice change.

Key Points

The aim is to identify new biomarkers that enhance early diagnosis and risk stratification in acute coronary syndromes.
Identified serum markers associated with inflammation and plaque instability
Evaluated traditional and novel biomarkers in patients with acute coronary syndromes
Assessed the prognostic value of BNP, IL-6, and PAPP-A levels in acute coronary events.
BNP levels significantly elevate during acute myocardial infarction, predicting higher mortality risk (P<0.01)
IL-6 levels correlate with plaque vulnerability and increased adverse outcomes (P<0.05)
PAPP-A is elevated in unstable angina and acute MI, indicating higher clinical risk (threshold 10 mIU/L).

Structured PICO

Do novel biomarkers (PAPP-A, hs-CRP, d-dimer, BNP) improve early diagnosis and risk stratification in patients with acute coronary syndrome compared to traditional markers?

Population

Patients with acute coronary syndrome (ACS), including unstable angina (UA) and acute myocardial infarction (MI)

Intervention

Novel biomarkers of plaque inflammation and neurohormonal activation (PAPP-A, hs-CRP, d-dimer, BNP, IL-6)

Comparator

Traditional serum markers of myocardial injury (CK-MB, cardiac troponin, myoglobin)

Outcome

Early diagnosis and risk stratification of acute coronary eventssurrogate

Novel biomarkers like PAPP-A, hs-CRP, d-dimer, and BNP provide earlier detection of plaque instability and neurohormonal activation in ACS, improving risk stratification before myocardial necrosis occurs.

Cite This Study

Futterman et al. (2002) studied this question.

synapsesocial.com/papers/6a77d51f576efb0ddaf7aadd https://doi.org/10.4037/ajcc2002.11.2.168

View Full Paper

Ask AI

Bookmark